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Abstract
Human cytomegalovirus (CMV), a member of the human herpesviruses, is a 
deoxyribonucleic acid virus that is ubiquitous in the world. After primary infec-
tion, CMV develops a latent state; however, when the defense of the immune 
system decreases in a host, it can reactivate. Human cytomegalovirus infections 
are acquired via several ways. CMV is spread through contact with infected bodily 
fluids in humans, whereas it occurs in pregnant women through close contact with 
young children or through sexual transmission. The clinical manifestations consist 
of non-specific symptoms or clinical findings. However, the patients with acute 
CMV infections are generally asymptomatic. Congenital CMV infection (present at 
birth) occurs via intrauterine transmission of the virus that is thought to be trans-
ferred to the developing fetus. The common clinical manifestations of congenital 
CMV infection are sensorineural hearing loss, petechiae, jaundice at birth, and 
hepatosplenomegaly. The vast majority of healthy children and adolescents infected 
with CMV infections are most often asymptomatic. Treatment is recommended to 
initiate to the infants who have a symptomatic infection or primary immunodefi-
ciency or asymptomatic infection with an isolated hearing loss. The diagnosis of 
congenital CMV infections should be considered when it is detected in the new-
borns with signs and symptoms consistent with congenital CMV disease or with 
abnormal neuroimaging consistent with CMV or newborns who have documented 
sensorineural hearing loss.
Keywords: human cytomegalovirus, transmission, symptoms, diagnosis
1. Introduction
Human cytomegalovirus (CMV), an infectious agent that is ubiquitous in the 
world population, is a member of human herpesvirus family including viruses such 
as Epstein-Barr virus, herpes simplex virus, and varicella zoster. CMV is the largest 
virus of the herpes family with a size of 190 nm. The structure of the virus includes 
a complex envelope composed of host cell-derived membrane studded and an icosa-
hedral capsid that contains the virion DNA. The tegument layer which describes an 
amorphous area between the envelope and the capsid induces strong adaptive immune 
responses including CMV-specific CD8+ cytotoxic T lymphocytes that are believed to 
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play a fundamental role in controlling CMV replication in the infected host. Humans 
are the only source of cytomegalovirus, and it might infect all races, ages, and genders.
Human cytomegalovirus, an opportunistic pathogen, is transmitted through 
solid organ/bone transplantation, placental pathway, sexual intercourse, blood 
transfusion, and in close contact with virus-spreading people. Similar to other 
herpesviruses, it leads to primary infection, secondary infection, latent infection, 
and reactivation or reinfection. In immunocompromised patients, CMV is respon-
sible for serious clinical symptoms. After primary infection, the viral genome 
forms an episomal circular form in myeloid progenitors and endothelial cells. 
Via TNF-alpha and type II interferon (IFN), latent CMV alter to active CMV and 
migrate to inflamed tissue where they further propagate during an inflammatory 
process and a context of immune activation. CMV is a viral agent that also causes 
intrauterine infections and brings about deafness and neurological anomalies in 
newborns. Cytomegalovirus has been associated with variable seroprevalence from 
45 to 100% in women of reproductive age and is never cleared from the host [1]. 
In immunocompetent adults, primary CMV infections are usually asymptomatic. 
Less commonly, fever, lymphadenopathy, and mononucleosis-like syndrome coexist 
with peripheral lymphocytosis. When people with impaired immune function are 
not treated, it can lead to infections with high mortality [2].
2. Epidemiology
Human cytomegalovirus infections are acquired via several ways. CMV is gener-
ally transmitted by infected fluids (e.g., saliva, breast milk, blood products) contact 
at home and nursery schools as community exposure. It is also thought that the 
contaminated urine contact might be a role of cytomegalovirus transmission [3]. 
Among the postnatal contaminations, breastfeeding is the most common course of 
CMV infection in young infants particularly in populations with high CMV serop-
revalence and high rates of breastfeeding from seropositive women during the first 
6 months of breastfeeding, peaking at 4–8 weeks after delivery, but the risk contin-
ues for the duration of breastfeeding. Even though it is thought that a local reactiva-
tion in the mammary glands of the mothers with latent CMV infection can cause the 
transmission to baby, but the transmission mechanism has not been clearly defined 
yet [4]. As a reservoir of virus, these infants excrete virus in the saliva and urine 
for prolonged periods to other infants, children, and adults. The preschool children 
with CMV can disseminate through stool, and they might infect their parents and 
teachers in baby care centers. Throughout childhood and early adulthood, CMV is 
transmitted by exposure to saliva and urine. Due to the fact that the virus is present 
in seminal and cervical fluids, it can also be transmitted by sexual way.
Congenital CMV infection (present at birth) occurs via intrauterine trans-
mission of the virus that is thought to be transferred to the developing fetus in 
approximately 30% of women undergoing primary infection during pregnancy or 
by reactivation in women previously immune for CMV rate on the order of 1–2% 
(vertical road). In the USA, Canada, Western Europe, and Australia, it is a common 
infection that is estimated to occur in about 5–7 per 1000 live births [5]. Rates as the 
highest with 2% in Asia and Africa have been described. Congenital CMV infec-
tion contributes to permanent disabilities such as hearing loss, vision loss, cerebral 
palsy, and/or cognitive impairment in children. Approximately 90% of newborn 
with congenital CMV are asymptomatic; however, the newborns are also at risk for 
CMV-associated disabilities [6].
Nosocomial infections with CMV emerge from exposure to blood products 
containing CMV. Transfusion-acquired CMV infections often caused symptomatic 
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illness including hepatitis and thrombocytopenia on children and adults. Fatal 
infections might be developed in newborns who are being born from women with-
out immunity of CMV due to lacking antibodies of CMV. Severe infection can also 
present in immunocompromised patients who received blood with CMV. Recently, 
using blood products from CMV-seronegative donors, the incidence of transfusion-
associated CMV infections has greatly decreased. Infections arising from CMV 
transferred in the allograft are major causes of morbidity in the early and late 
period after transplantation. Even if the antiviral therapy is applied, CMV infection 
causes long-term graft dysfunction and graft loss, particularly in cardiac and lung 
transplant recipients [7].
3. Clinical manifestations
The clinical manifestations consist of non-specific symptoms or clinical 
findings. However, the patients with acute CMV infections are generally asymp-
tomatic. During the intrauterine period, babies infected with CMV usually do 
not expose symptoms at birth. However, 10–15% of them exhibit symptoms and 
become symptomatic at a later stage of their infancy. The common clinical mani-
festations of congenital CMV infection are sensorineural hearing loss, petechiae, 
jaundice at birth, hepatosplenomegaly, small size for gestational age, microceph-
aly, lethargy and/or hypotonia, poor suck, chorioretinitis, seizures, hemolytic 
anemia, and pneumonia [8]. The sensorineural hearing loss may be detectable at 
birth; however, approximately 30% of the cases have delayed onset. Table 1 shows 
clinical manifestations, treatment, and outcome of congenital CMV infections. 
Congenital CMV associated with hearing loss is bilateral in 71% of children. Eye 
examination of symptomatic congenital CMV includes chorioretinitis that is the 
most common ocular abnormality, retinal scars, optic atrophy, central vision loss, 
and strabismus. The endocrinologic manifestations consist of Graves’ disease 
and diabetes insipidus and renal disease, such as nephrotic syndrome. Congenital 
CMV infections are the leading cause of other long-term neurodevelopmental 
disabilities and can also affect other organ systems such as gastrointestinal system 
including Menetrier disease. Ascites, myocarditis, cardiomyopathy, ventricular 
trabeculations, and enterocolitis are also seen among manifestations of the 
congenital CMV in symptomatic neonates [9]. Despite the fact that the overall 
mortality rate among infants with congenital CMV infection is approximately 
4–8% within the first year of life, congenital CMV infection might be associated 
with mortality in premature infants and infants with primary immune disorders 
of T cells or natural killer cells. Rarely, many infants without underlying disease 
Clinical manifestations Treatment Outcome
Congenital 
CMV 
infections
At birth, 90% of cases are 
asymptomatic
Petechiae, jaundice at birth, 
hepatosplenomegaly, petechial 
rash, small size for gestational age, 
thrombocytopenia, microcephaly, 
intracranial calcifications, 
polymicrogyria, ventriculomegaly, 
sensorineural hearing loss, 
chorioretinitis, seizures
Asymptomatic 
infants do not 
require antiviral 
treatment
Ganciclovir or 
valganciclovir 
for symptomatic 
infections
Overall mortality rate is 
4–8%
Mortality rate with severe 
fulminant disease is as high 
as 30%. Long-term sequelae 
include hearing loss, cerebral 
palsy, intellectual disability, 
vision impairment, and 
seizures
Table 1. 
Clinical manifestations, treatment, and outcome of congenital CMV infections.
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have the risk of mortality as high as 30% caused by a fulminant course. Death is 
usually caused by viral-associated hemophagocytic syndrome or severe end-organ 
disease of the liver, lungs, bone marrow, or central nervous system. Even if the 
infants with a life-threatening disease associated with congenital CMV are able to 
live, neurological sequelae might persist for a lifetime (e.g., microcephaly, intel-
lectual disability, cerebral palsy, and hearing disorders) [10, 11]. Pneumonitis, 
signs of viral sepsis, thrombocytopenia, and coinfections are more likely to 
have existed in premature infants than term neonates [7]. Additionally, preterm 
infants can also present with a classical triad of apneas, bradycardia, and gray 
pallor describing CMV sepsis-like syndrome [12]. The cases with perinatal infec-
tions which are generally not associated with any clinical manifestations can be 
acquired during birth or ingestion of CMV-containing breast milk. Disseminated 
infections associated with end-organ disease and death might be seen in extremely 
premature infants or infants born to nonimmune women.
The vast majority of healthy children and adolescents infected with CMV infec-
tions (acquired CMV infection) are most often asymptomatic (Tables 2 and 3). 
However, the remaining patients (approximately 10%) could present with several 
mild or moderate symptoms. A clinical entity named mononucleosis-like syndrome 
with no heterophile antibody titers or positive monospot tests is characterized by 
fever, fatigue, pharyngitis, adenopathy (especially cervical adenopathy), and hepa-
titis. A headache, abdominal pain with diarrhea, arthralgias, and rash can also be 
observed in mononucleosis-like syndrome in acquired CMV infection. Laboratory 
findings mimic to EBV-related mononucleosis syndrome like lymphocytosis or 
lymphopenia with thrombocytopenia and elevated transaminases [13]. Unusual 
manifestations or complications of acquired CMV infections in healthy individuals 
consist of pneumonitis, myopericarditis, hemolytic anemia, viral hemophagocytic 
syndrome, granulomatous hepatitis, Guillain-Barré syndrome, and meningoen-
cephalitis [7].
When a reactivation of the endogenous virus and infection from the trans-
planted organ or from blood product transfusion take place in immunocompro-
mised children and adolescents, serious CMV disease can be observed which is 
linked to the underlying disease process responsible for the immunosuppression 
(Table 4). Non-specific symptoms such as fever, malaise, and leukopenia might be 
seen in all types of patients. Patients with renal transplant are at graft loss; the liver 
recipients are most likely to be associated with hepatitis and colitis. Early myocardi-
tis followed by late atherosclerosis is seen in heart transplant recipients. Recipients 
Clinical manifestations Treatment Outcome
Early 
postnatal 
CMV 
infection
Term infants: Most infants are 
asymptomatic
Fever, hepatosplenomegaly, mild 
pneumonitis, abnormal blood 
counts, abnormal liver function 
tests
Premature and VLBW infants: 
Infection can be severe and 
life-threatening
Sepsis-like syndrome, 
hepatosplenomegaly, 
pneumonitis, hepatitis, NEC, 
abnormal blood counts
Most term infants 
and asymptomatic 
preterm infants do 
not require antiviral 
treatment
Ganciclovir or 
valganciclovir for 
severe symptomatic 
infections in 
premature infants
Term infants: no permanent 
sequelae. Premature and 
VLBW infants: mortality 
rate with symptomatic 
infection is 5–10%
There does not appear to be 
increased risk of hearing 
loss, cerebral palsy, or 
other neurodevelopmental 
disabilities; however, 
long-term outcomes are not 
clearly understood
Table 2. 
Clinical manifestations, treatment, and outcome of early-postnatal CMV infection.
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with lung and bone marrow transplant generally show a state of pneumonia. 
Children with human immunodeficiency virus (HIV) and CMV coinfection tend to 
have retinitis, colitis, pneumonitis, and encephalitis/encephalopathy [14].
4. Diagnosis
The diagnosis of congenital CMV infections should be considered when it is 
detected in the newborns with signs and symptoms consistent with congenital CMV 
disease or with abnormal neuroimaging consistent with CMV or newborns who 
have documented sensorineural hearing loss (SNHL). Newborns who are possessed 
by a mother with seroconversion positivity or with positive CMV immunoglobulin 
G (IgG) and CMV immunoglobulin M (IgM) antibody or with mononucleosis-like 
illness during pregnancy should also be evaluated for congenital CMV infections. 
Infants with an abnormal T-cell receptor in newborn screening should be suspected 
for congenital CMV infections. The reliable diagnosis of congenital CMV infec-
tions must be detected through sources of virus and viral nucleic acids from urine, 
saliva, and blood within the first 3 weeks of life in infants. The newborns with 
suspected congenital CMV infection should be analyzed by viral culture, modified 
culture (also called rapid culture or shell vial assay), and polymerase chain reaction 
(PCR) for diagnosis. Detection of CMV by PCR in blood or plasma samples is more 
accurate than other diagnostic tests [15]. Due to the fact that the polymerase chain 
reaction provides quantitative results, urine and saliva that include high levels of 
CMV DNA are generally evaluated in newborns suspected with CMV.
Primary infection of CMV in nonimmunocompromised individuals requires 
evidence of an IgM reactivity for CMV in blood. It can persist for months depend-
ing on the sensitivity of the particular assay. Due to the fact that the infected 
Clinical manifestations Treatment Outcome
CMV infection in 
immunocompetent 
children and adolescents
Most children are asymptomatic
Fever, fatigue, pharyngitis, 
mononucleosis-like syndrome, 
adenopathy, hepatitis, headache, 
abdominal pain, diarrhea, arthralgias, 
rash, lymphocytosis or lymphopenia, 
thrombocytopenia, abnormal liver 
function tests, negative monospot test
Antiviral 
treatment is 
generally not 
indicated
Supportive 
care with 
hydration and 
fever control
No permanent 
sequelae
Table 3. 
Clinical manifestations, treatment, and outcome of CMV infection in immunocompetent children and 
adolescents.
Clinical manifestations Treatment Outcome
CMV infection in 
immunocompromised 
children and adolescents
Infection can be severe and 
life-threatening
Fever, malaise, leukopenia, hepatitis, 
pneumonitis, colitis, graft loss (in 
patients with organ transplant), 
myocarditis, retinitis, encephalitis/
encephalopathy (especially in 
patients with HIV)
Ganciclovir or 
valganciclovir
High risk of 
morbidity 
and 
mortality; 
depends in 
part on the 
underlying 
condition
Table 4. 
Clinical manifestations, treatment, and outcome of CMV infection in immunocompromised children and 
adolescents.
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individuals can intermittently shed virus, body fluids such as saliva or urine do 
not provide the diagnosis of CMV infection. Polymerase chain reaction-based 
methods are also utilized for diagnosis of urine, saliva, and blood and in tissue 
specimens obtained at biopsy. A combination with immunofluorescence detec-
tion of CMV-encoded and conventional culture of CMV using human dermal 
fibroblasts remains standard in many institutions. Characteristic nuclear (and 
cytoplasmic) inclusions (owl’s eye inclusions) can be detected by histologic stains 
in tissue specimens.
5. Treatment
Treatment is recommended to be initiated to the infants who have a symptom-
atic infection or primary immunodeficiency or asymptomatic infection with an 
isolated hearing loss for congenital CMV infection within the first month of life. At 
the first line, ganciclovir through intravenous route and its orally available prodrug, 
valganciclovir, for treatment of congenital CMV disease are indicated. Randomized 
clinical trials of the Collaborative Antiviral Study Group suggested that 6 weeks of 
ganciclovir treatment could confine hearing loss and improve developmental out-
come in infants infected symptomatically. In addition, infants with severe perinatal 
CMV infection caused by breast milk could be treated with ganciclovir [7, 16].
In the normal host and early-postnatal infections in term asymptomatic infants, 
treatment of acquired CMV infections is not recommended. However, treatment 
must be implemented in preterm or very-low-birth-weight (VLBW) infants with 
severe infection.
Immunocompromised hosts are recommended with antiviral therapy with gan-
ciclovir in children with active CMV disease. Even if there are no signs or symptoms 
of end-organ disease in immunocompromised children, it is also suggested to apply 
the antiviral therapy due to CMV viremia (e.g., positive or rising quantitative PCR). 
Treatment of CMV disease in immunocompromised pediatric patients consists of 
ganciclovir and oral valganciclovir similar to that in adults. Treatment is usually 
given in the form of intravenous ganciclovir or oral valganciclovir for 4–6 weeks on 
average [17]. Patients are recommended to seek for antiviral treatment monitoriza-
tion with white blood cell count, AST, and ALT regularly. In some cases, when the 
antiviral therapy cannot improve clinical or virologic response within several weeks 
of treatment with ganciclovir or valganciclovir, foscarnet might be integrated to the 
treatment. Another specific anti-CMV treatment is cidofovir that may be used in 
children with careful monitoring of renal function and metabolic condition when 
antiviral resistance occurs.
6. Prevention
6.1 Passive immunoprophylaxis
Intrauterine disease could be prevented from infection through passive transfer 
of anti-CMV antibodies. However, this transfer is not successful in allograft recipi-
ents. A neonatal transfer is prevented from CMV infection using CMV-seronegative 
or leukocyte-reduced blood for extremely preterm infants. Freezing/thawing or 
pasteurization eliminates the risk of transfusion-related CMV infection in breast 
milk contaminated with CMV, however; it might not be complete. The passive 
transfer of anti-CMV antibodies is recommended to limit transmission and disease 
in pregnant women with primary CMV infection.
7Human Cytomegalovirus Infection: Biological Features, Transmission, Symptoms, Diagnosis...
DOI: http://dx.doi.org/10.5772/intechopen.81833
6.2 Active immunoprophylaxis
A number of different vaccine platforms that will be available for prevention of 
CMV disease in newborns and immunocompromised patients have been evaluated 
in clinical trials. However, none are licensed.
7. Final considerations
Cytomegalovirus is a common agent that can be seen all over the world. 
Although CMV is generally asymptomatic in healthy individuals, it can lead to 
severe infection in individuals with immune deficiency. During pregnancy, CMV 
also cause significant disabilities in babies whose mother has CMV. After its pri-
mary infection, the virus remains as an inactive form in the host throughout the 
life. Recurrent CMV infections may occur with the reactivation of the silent virus. 
Due to the fact that congenital CMV infections are asymptomatic, a hearing test is 
strongly recommended to the newborns.
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